ABSTRACT
Introdução: A obesidade é um dos principais problemas de saúde enfrentados pela população e sua incidência cresce gradativamente nas últimas décadas. Em meio à epidemia global de obesidade, os procedimentos bariátricos aumentaram expressivamente e, apesar do crescente número dos procedimentos pós-bariátricos, esses não se equivalem ao número de cirurgias bariátricas. Métodos: Foram coletados dados do registro de saúde pública (DATASUS) entre 2008 e 2019 para análise dos parâmetros selecionados, com avaliação das principais técnicas de dermolipectomia pós-bariátrica, sua distribuição em território nacional, seu tempo de internação, sua mortalidade, os custos para o Sistema Público, a comparação entre as dermolipectomias pós-bariátricas e a distribuição dos procedimentos bariátricos no território nacional. Além disso, comparou-se as dermolipectomias e a distribuição de cirurgiões plásticos no Brasil. Resultados: Um aumento de 164% foi evidenciado no número de dermolipectomias pós-bariátricas durante o período estudado. A dermolipectomia abdominal pós-bariátrica foi o procedimento mais realizado, sendo responsável por 65% dos procedimentos, seguido da dermolipectomia braquial (14,8%), crural (14,7%) e circunferencial (4,7%). Observou-se uma desigualdade na distribuição dos procedimentos pós-bariátricos entre as macrorregiões brasileiras, sendo a Região Sudeste com o maior número percentual (49,8%) de dermolipectomias. Conclusões: Apesar do aumento progressivo do número de dermolipectomias pós-bariátricas, elas não acompanharam o número de procedimentos bariátricos em território nacional. Por isso, há necessidade de um crescimento paralelo entre ambas, para que haja uma complementação no tratamento desses pacientes. Sendo assim, poderá existir melhora na distribuição das dermolipectomias no território nacional, fazendo com que mais pacientes possam ser beneficiados.
Introduction: Obesity is one of the main health problems faced by the population, and its incidence has gradually increased in recent decades. Amid the global obesity epidemic, bariatric procedures have increased significantly and, despite the growing number of post-bariatric procedures, these are not equivalent to the number of bariatric surgeries. Methods: Data were collected from the public health registry (DATASUS) between 2008 and 2019 to analyze the selected parameters, with an assessment of the main post-bariatric dermolipectomy techniques, their distribution in the national territory, their length of stay, their mortality, costs for the Public System, the comparison between post-bariatric dermolipectomies and the distribution of bariatric procedures in the national territory. Furthermore, dermolipectomies and the distribution of plastic surgeons in Brazil were compared. Results: An increase of 164% was evidenced in the number of postbariatric dermolipectomies during the studied period. Post-bariatric abdominal dermolipectomy was the most performed procedure, accounting for 65% of the procedures, followed by brachial (14.8%), crural (14.7%) and circumferential (4.7%) dermolipectomy. There was an inequality in the distribution of post-bariatric procedures among Brazilian macro-regions, with the Southeast Region having the highest percentage (49.8%) of dermolipectomies. Conclusions: Despite the progressive increase in post-bariatric dermolipectomies, they did not follow the number of bariatric procedures in the national territory. Therefore, there is a need for a parallel growth between both so that there is complementation in treating these patients. Then, there might be an improvement in the distribution of dermolipectomies in the national territory, allowing more patients to benefit.
ABSTRACT
INTRODUCTION: The reconstruction of defects in thoracic wall remains a challenge for plastic surgeons. Advances in surgical treatment of illnesses of thoracic wall have been fostering the treatment of lesions within more advanced levels. Consequently, larger and more complex defects are generated, demanding soft tissue covering and framework repair. OBJECTIVE: The aim of this study was to report the experience in chest wall reconstruction and demographics of a tertiary cancer center. METHODS: All patients submitted to thoracic wall reconstruction by the plastic surgery department from January 2012 to May 2018 in a tertiary cancer center were evaluated. RESULTS: Thirty-two patients have undergone thoracic wall reconstruction. The majority of patients in our series were submitted to surgical treatment of locally advanced breast cancer (84.3%). The most common defect location was the right anterolateral region (65.6%). The latissimus dorsi musculocutaneous flap was the most used in thoracic wall reconstructions. Three cases of thoracectomy with rib resection were reconstructed with methylmethacrylate and polypropylene surgical mesh associated with musculocutaneous flap. Four patients presented major complications, and 12 patients (37.5%) presented minor complications. There were no deaths related to procedures or instability of thoracic wall. Twenty-two patients presented progression of the disease, and 16 died due to the primary pathology. CONCLUSIONS: Extended resection of the chest wall is associated in most cases with advanced disease, especially advanced breast cancer. Despite poor prognosis associated to locally advanced disease, it is imperative to perform chest wall reconstruction and allow the patient to continue adjuvant therapy (radiotherapy or chemotherapy) and improve quality of life.
Subject(s)
Mammaplasty , Myocutaneous Flap , Plastic Surgery Procedures , Thoracic Surgical Procedures , Thoracic Wall , Humans , Quality of Life , Surgical Mesh , Thoracic Wall/surgeryABSTRACT
PURPOSES: To evaluate the effect of subconjunctival bevacizumab in an experimental model of neovascularization in rabbit cornea. Determine its effect on vessels extension, inflammation, epithelialization of the cornea and whether the evaluation method used is appropriate to compare neovascular models. METHODS: Experimental, prospective, randomized, blinded study in twenty rabbits subjected to chemical trauma with sodium hydroxide at 1N divided into two groups. The study group received subconjunctival injection of 0.15 ml (3.75 mg) of bevacizumab and was compared with the control group that received subconjunctival injection of 0.15 ml saline solution. After 25 days, digital photographic analysis was performed to assess the vessel's extension and inflammation/diameter according to pre-established criteria. Histopathology of the cornea, which evaluated the state of the epithelium and the number of polymorphonuclear cells was also studied. RESULTS: The length of the neovessels was greater in the control group compared to the study group (P=<0.001). There was no difference in inflammation/vessel diameter between groups. Histopathology analysis showed that there was no difference between groups for the variables state of the epithelium and number of polymorphonuclear cells. The concordance analysis for the variable extension of the vessels and the variable inflammation/vessel diameter was estimated with Kappa coefficients of 0.705 and 0.500 respectively, indicating a good level of agreement in different evaluations and validating the method. CONCLUSIONS: The experimental model is adequate and can be reproduced to evaluate other drugs in the cornea. Bevacizumab inhibit the neovessels' growth but was not effective in preventing the inflammatory response. The drug did not delay the reepithelialization of the cornea.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/therapeutic use , Burns, Chemical/drug therapy , Corneal Neovascularization/prevention & control , Animals , Antibodies, Monoclonal, Humanized , Bevacizumab , Burns, Chemical/complications , Burns, Chemical/pathology , Corneal Neovascularization/etiology , Corneal Neovascularization/pathology , Disease Models, Animal , Male , Prospective Studies , Rabbits , Random AllocationABSTRACT
OBJETIVOS: Avaliar a ação do bevacizumabe subconjuntival em modelo experimental de neovascularização em córnea de coelho. Analisar se o modelo de avaliação empregado é adequado e comparar entre os grupos a extensão dos vasos, inflamação e re-epitelização da córnea. MÉTODOS: Estudo experimental, prospectivo em 20 coelhos submetidos a trauma químico com hidróxido de sódio a 1 N divididos em dois grupos, Imediatamente após a queimadura, o grupo tratado recebeu injeção subconjuntival de 0,15 ml (3,75 mg) de bevacizumabe e o grupo controle, injeção subconjuntival de 0,15 ml de soro fisiológico a 0,9 por cento. Após 25 dias, foi realizada análise fotográfica digital para avaliar a extensão e inflamação/calibre dos vasos segundo critério pré-estabelecido e estudo histopatológico da córnea, no qual foi avaliado o estado do epitélio e o número de polimorfonucleares. RESULTADOS: A extensão dos neovasos corneanos foi menor no grupo estudo em relação ao controle (p<0,001). Não houve diferença significativa entre os grupos na inflamação/calibre dos vasos. A análise histopatológica mostrou que não ocorreu diferença entre os grupos nas variáveis estado do epitélio e número de polimorfonucleares. A análise de concordância para a variável extensão dos vasos e para a variável inflamação/calibre dos vasos teve uma estimativa do coeficiente de Kappa respectivamente de 0,705 e 0,500 indicando bom grau de concordância nas diferentes avaliações cegadas, validando o método empregado. CONCLUSÕES: O modelo de avaliação foi adequado e pode ser reproduzido para avaliar outras drogas na córnea. O bevacizumabe inibiu a neovascularização corneana, porém não foi eficaz em reduzir o processo inflamatório. A droga não atrasou a re-epitelização da córnea.
PURPOSES: To evaluate the effect of subconjunctival bevacizumab in an experimental model of neovascularization in rabbit cornea. Determine its effect on vessels extension, inflammation, epithelialization of the cornea and whether the evaluation method used is appropriate to compare neovascular models. METHODS: Experimental, prospective, randomized, blinded study in twenty rabbits subjected to chemical trauma with sodium hydroxide at 1N divided into two groups. The study group received subconjunctival injection of 0.15 ml (3.75 mg) of bevacizumab and was compared with the control group that received subconjunctival injection of 0.15 ml saline solution. After 25 days, digital photographic analysis was performed to assess the vessel's extension and inflammation/diameter according to pre-established criteria. Histopathology of the cornea, which evaluated the state of the epithelium and the number of polymorphonuclear cells was also studied. RESULTS: The length of the neovessels was greater in the control group compared to the study group (P=<0.001). There was no difference in inflammation/vessel diameter between groups. Histopathology analysis showed that there was no difference between groups for the variables state of the epithelium and number of polymorphonuclear cells. The concordance analysis for the variable extension of the vessels and the variable inflammation/vessel diameter was estimated with Kappa coefficients of 0.705 and 0.500 respectively, indicating a good level of agreement in different evaluations and validating the method. CONCLUSIONS: The experimental model is adequate and can be reproduced to evaluate other drugs in the cornea. Bevacizumab inhibit the neovessels' growth but was not effective in preventing the inflammatory response. The drug did not delay the reepithelialization of the cornea.
